Copenhagen, Denmark; July 26, 2011 – Genmab A/S (OMX: GEN) announced today that the Arzerra® (ofatumumab) net sales during the second quarter of 2011 were GBP 10.5 million (approximately DKK 88.6 mill
-
Copenhagen, Denmark; July 26, 2011 – Genmab A/S (OMX: GEN) announced today that the Arzerra
(ofatumumab) net sales during the second quarter of 2011 were GBP 10.5 million (approximately DKK 88.6 million). This figure consists of net sales in the U.S. of GBP 7.4 million (approximately DKK 62.4 million) and in the rest of the world GBP 3.1 million (approximately DKK 26.2 million). Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 17.7 million.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind